The Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) collects real-world data from patients receiving care across a variety of clinical settings who are being evaluated for or treated with new, approved Alzheimer’s treatments. The evidence gathered will be used to advance research, improve health equity and patient care, and inform Alzheimer’s and other dementia treatment practices.
ALZ-NET provides resources and education for clinicians and health care providers. It is also a platform for patients to access resources about Alzheimer's, including locating a medical expert in the network.
A word from Maria C. Carrillo, Ph.D., Chief Science Officer, Alzheimer's Association
"We are entering a new phase of Alzheimer's treatment. Data from real-world settings often provide unique insights into the way patients receive real-world care beyond what can typically be learned through clinical trials. In addition, ALZ-NET aspires to alleviate health inequity through an inclusive approach in a broad patient population treated in real-world settings."
Why should clinicians participate in
Stay up to date on the latest developments in dementia research and care when you participate in ALZ-NET. The network provides value-driven solutions that address clinician time commitment and education, resources, and tools to enhance the clinician's knowledge, comfort, and ability to provide care.
ALZ-NET is approved by the Centers for Medicare and Medicaid Services (CMS) as a Coverage with Evidence Development (CED) study and can be used as a pathway to Medicare coverage for anti-amyloid Alzheimer's therapies that have received traditional FDA approval.
Other benefits to participating in ALZ-NET include:
- Access to continuing education opportunities for all levels of health care providers.
- Educational support for patient assessment and diagnosis, appropriate use of newly approved therapies, and safety monitoring.
- Imaging resources, including education on PET and MRI interpretation.
- Dementia care resources.
- Opportunities to participate in funded pilot testing of care innovations.
What qualifications are needed to participate?
Interested sites must complete the Site Registration and Feasibility Survey. This survey will collect initial information, including but not limited to:
- Access to accredited and appropriate radiological services for diagnostic and safety brain imaging.
- Access to infusion services.
- Access to emergency services.
- Access to standard cognitive, behavioral and functional assessments used in dementia care.
Information that describes the site's patient population and enrollment include but is not limited to:
- Estimated race and ethnicity of patient population.
- Estimated enrollment capabilities based on the ALZ-NET eligibility criteria.
Site investigator qualifications
- Must hold credentials that authorize prescription of novel FDA-approved therapies.
- Novel FDA-approved therapies for AD are drugs that have received approval as treatments for Alzheimer's disease (AD) from the U.S. Food and Drug Administration since 2021.
- Site investigator may be a physician, physician assistant, or nurse practitioner.
- All site investigators must have the appropriate education and ability for contact time for evaluation and care of adults with cognitive impairment or dementia.
How do clinicians get started with ALZ-NET?
After reading the ALZ-NET Protocol Synopsis (PDF), qualified clinicians and providers interested in joining ALZ-NET must submit the Site Registration and Feasibility Survey. Sites will be reviewed and approved by ALZ-NET. If your site is invited to participate, you will receive instructions to continue the process.
Clinicians at ALZ-NET sites will consent and register into the network patients who are being evaluated for or treated with new FDA-approved Alzheimer's disease therapies. Then, clinicians will collect quality clinical and safety data from patients as part of their real-world care.
For questions about timing and participation, or other inquiries about ALZ-NET, please contact email@example.com.
ALZ-NET provides training opportunities and resources to clinicians and participating sites.
ALZ-NET International connects ALZ-NET with Real-World Data (RWD) platforms globally, providing opportunities to share resources, exchange ideas and amplify impact. ALZ-NET International partners meet quarterly to share updates and initiatives, including at an annual in-person meeting at the Alzheimer’s Association International Conference (AAIC). Collaboration between ALZ-NET International partners is encouraged through the formation of working groups to explore areas of mutual interest.
International real-world data platforms and platforms in development are invited to apply for the Alzheimer's Association Funding Program for Global Real-World Data Platforms (ALZ-RWD), which aims to advance RWD by providing funds to develop, expand and align RWD platforms' infrastructure, data and impact globally.
For more information on ALZ-NET International, please email Emily Meyers at firstname.lastname@example.org.
ALZ-NET is sponsored by the Alzheimer's Association.
ALZ-NET is managed by the American College of Radiology.
Other partners include: